Technoeconomic evaluation of multiple MSMPR crystalliser configurations for continuous cyclosporine crystallisation by Diab, Samir & Gerogiorgis, Dimitrios
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Technoeconomic evaluation of multiple MSMPR crystalliser
configurations for continuous cyclosporine crystallisation
Citation for published version:
Diab, S & Gerogiorgis, D 2017, 'Technoeconomic evaluation of multiple MSMPR crystalliser configurations
for continuous cyclosporine crystallisation' Organic Process Research & Development, vol. 21, no. 10, pp.
1571.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Organic Process Research & Development
Publisher Rights Statement:
GOLD OPEN ACCESS ARTICLE
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Technoeconomic Evaluation of Multiple Mixed Suspension-Mixed
Product Removal (MSMPR) Crystallizer Conﬁgurations for
Continuous Cyclosporine Crystallization
Samir Diab and Dimitrios I. Gerogiorgis*
Institute for Materials and Processes (IMP), School of Engineering, University of Edinburgh, The King’s Buildings, Edinburgh, EH9
3FB, United Kingdom
ABSTRACT: Continuous crystallization using Mixed Suspension-Mixed Product Removal (MSMPR) crystallizers has been
demonstrated as a feasible method for implementing continuous separations in pharmaceutical manufacturing processes. This
work conducts a steady-state process modeling and simulation study of the continuous cooling crystallization of cyclosporine,
comparing processes with and without solids recycle for their technoeconomic viability. The model describes population balance
equations, crystallization kinetics, and process mass balances to compare attainable crystallization and plantwide yields of
diﬀerent process conﬁgurations. Total cost components using an established economic analysis methodology are compared for
varying numbers of crystallizers, operating temperatures, total crystallizer cascade residence times and API feed concentrations.
Economic analyses and the calculation of normalized cost components with respect to total crystallizer volumes identify the
process without recycle as the most economically viable option, achieving the lowest total costs and low E-factors for
pharmaceutical processes. The sensitivity of total costs to the selected total residence times for economic analyses highlights the
need for rigorous comparison methodologies. This work identiﬁes the need for technoeconomic optimization studies of
continuous crystallization processes to establish the optimal design of manufacturing campaigns prior to further development.
1. INTRODUCTION
Continuous pharmaceutical manufacturing (CPM) has been
established as a promising new paradigm with the potential for
signiﬁcant technoeconomic beneﬁts for the pharmaceutical
industry.1 While the current batch manufacturing methods have
advantages such as speciﬁc product recall, ﬂexible equipment
usage and well-established analytical methods for quality
control, they imply large material inventories, signiﬁcant
intermediate storage and poor mixing and heat transfer
eﬃciencies.2−4 Various demonstrations of continuous ﬂow
syntheses,5−7 product formulation stages8 and fully end-to-end
production campaigns9−13 show the initiative of academic and
industrial researchers to facilitate the transition toward
continuous methods. Despite these eﬀorts, a stagnancy against
widespread adoption of CPM exists due to investments in
batchwise infrastructures and limited technological expertise in
continuous pharmaceutical processes compared to current
techniques.14,15 Furthermore, the limited number of demon-
strated continuous pharmaceutical puriﬁcations and separations
presents a bottleneck to realizing end-to-end CPM.
Crystallization is an essential unit operation in pharmaceut-
ical manufacturing prior to downstream processing. Batch
crystallization techniques are currently dominant in the
pharmaceutical industry; however, batch-to-batch variability is
an issue for the strict purity regulations placed upon
pharmaceutical products.16 Continuous crystallization operates
under steady-state conditions, allowing higher reproducibility
and better control of important crystal properties such as the
purity and the size distribution, which directly aﬀect the
bioavailability of the product; however, as continuous processes
do not discharge at equilibrium, they tend to achieve lower
yields than batch crystallizations.17 Systematic investigation of
continuous crystallization processes for pharmaceutical manu-
facturing is required to realize the attainable beneﬁts compared
to existing batch methods.
Continuous crystallizer designs applicable for the pharma-
ceutical industry are categorized as plug ﬂow (PF), oscillatory
baﬄed crystallizers (OBCs) or Mixed Suspension-Mixed
Product Removal (MSMPR) crystallizers. PF crystallizers are
suited to systems with fast crystal growth kinetics and short
residence times and can attain narrow crystal size distribu-
tions,18 but fouling and clogging in narrow tube diameters is an
important technical issue.19 OBCs are another emerging
technology, which enhance heat and mass transfer, but have
issues handling streams with high solid loadings.20 Various
experimental and modeling studies in OBCs have been
conducted for the estimation of crystallization kinetics, proof-
of-concept demonstrations and design and optimization
processes.21−26
MSMPR crystallizers are idealized stirred tank designs better
suited for systems with slower crystallization kinetics and can
easily be adapted from existing jacketed agitated vessels for
continuous applications.27 For this reason, MSMPR crystallizers
to produce active pharmaceutical ingredients (APIs) have been
demonstrated in several experimental and theoretical studies.
The continuous crystallization of aliskiren hemifurate using two
MSMPR crystallizers achieved both high yield and purity;
growth and nucleation kinetic parameters were regressed, and
yields and purities were optimized by varying MSMPR
residence time and operating temperature.28 The design was
subsequently implemented into a CPM pilot plant.9 Signiﬁcant
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work in the MSMPR crystallization of paracetamol has been
made using a series of crystallizers29 with the additional
consideration of ﬁltration units,30 slurry transfer31,32 and
membrane separations33,34 to further develop these processes.
Furthermore, various studies have used MSMPR crystallizers to
control attainable crystal size distributions35−37 polymorphic
states38−40 and perform enantiomeric separations41,42 for
diﬀerent products.
Experimental studies are often coupled with process
modeling and simulation methodologies to construct predictive
models to screen various process conditions and conﬁgurations
while circumventing time and ﬁnancial investments.43 Compu-
tational studies for the MSMPR crystallization of various APIs
are demonstrated in the literature.24,44−48 A recent study
conducted rigorous mathematical modeling and control around
a steady-state set point for the MSMPR crystallization of
paracetamol, demonstrating reduced residence times and
comparable yields with the batch process.49 Another study
performed kinetic parameter estimation and multiobjective
optimization for the continuous crystallization of paracetamol
in two MSMPRs in series.29
Another API whose continuous crystallization has been
demonstrated in MSMPR crystallizers is cyclosporine. Cyclo-
sporine is an immunosuppressant drug listed on the World
Health Organisation (WHO) Essential List of Medicines for
the prevention of organ transplant rejection50 with additional
applications in the treatment of psoriasis, rheumatoid arthritis
and dermatitis.51 The continuous cooling crystallization of
cyclosporine in MSMPR crystallizers has been investigated via
experimental and process modeling studies in the literature;
growth and nucleation kinetic parameters have been
estimated,52 and the viability of conﬁgurations with various
recycle options53−55 have been considered. Process conﬁg-
urations with mother liquor recycle have been investigated,55
but decreases in purity as a result of recycling made the process
inferior to conﬁgurations with and without solids recycle.53,54
The choice of recycle option signiﬁcantly aﬀects the type and
capacity of equipment required, and the selection of feasible
and viable operating regimes is paramount to successful process
development.56,57 Experimental work has yet to conduct fully
rigorous, systematic comparisons of feed conditions, operating
temperatures, recycle ratios and feed point locations on the
performance of continuous cooling crystallization of cyclo-
sporine. A systematic technoeconomic analysis comparing
diﬀerent ﬂowsheets is also yet to be conducted; costing of
diﬀerent conﬁgurations aids the elucidation of the best
candidate process prior to scale-up.58
This paper describes the steady-state process modeling for a
systematic technoeconomic comparison of two ﬂowsheet
conﬁgurations for continuous cyclosporine crystallization in
MSMPR crystallizers: the process without recycle and the
process with solids recycle, based on experimentally demon-
strated conﬁgurations.53,54 First, we describe the diﬀerent
ﬂowsheets and operating variables considered in each
conﬁguration. We then describe the process modeling method-
ologies, combining fundamental population balance equations,
crystallization kinetics and process mass balances for MSMPR
crystallization. Calculated attainable crystallization and plant-
wide yields and material eﬃciencies are compared for diﬀerent
conﬁgurations to establish the most promising candidate
conﬁgurations for cost comparison. Subsequently, we conduct
an economic analysis to compare candidate processes to
evaluate the most viable conﬁguration for application. Finally,
discussion of the results and conclusions on the technoeco-
nomic viability of diﬀerent continuous processes for cyclo-
sporine crystallization are presented with an outlook to future
work in this vibrant research ﬁeld.
2. PROCESS FLOWSHEETS
Here, we present ﬂowsheet conﬁgurations and their operating
variables for continuous cyclosporine crystallization. All
conﬁgurations are based upon experimental demonstrations
for continuous cooling crystallisation of cyclosporine from
acetone.53,54 All plant designs are speciﬁed to produce 100 kg
of cyclosporine per annum under steady-state conditions,
consistent with our recent publications.59−63 The desired plant
capacity can easily be altered in the proposed framework.
Figure 1 shows the ﬂowsheet for the MSMPR cooling
crystallization of cyclosporine without recycle based on recent
experiments.53 This conﬁguration features a cascade of
MSMPR crystallizers for continuous cyclosporine crystallization
with magma transfer between crystallizers using peristaltic
pumps.
Figure 2 shows the ﬂowsheet for the MSMPR crystallization
of cyclosporine with solids recycle.54 A gravity-driven
separation following the ﬁnal crystallizer in the cascade allows
Figure 1. MSMPR crystallization of cyclosporine without process recycle.53
Figure 2. MSMPR crystallization of cyclosporine with solids recycle.54
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a concentrated solid slurry to be recycled back to the
crystallizer cascade. We do not consider the eﬀect of particle
size distributions in this work as downstream processes such as
wet-milling are not considered. The extent of solids recycle to
each crystallizer is altered by varying the amount of material fed
back to the process from the bottom of the gravity-driven
separator. The concentration of the recycled solid slurry is
controlled by the clear liquor removal ratio (x = F2N+2/FN =
0.287, as in the experimental demonstration54); the removed
mother liquor from the top of the column (F2N+2) and that in
the product magma (F2N+3) are discarded as waste.
The experimental demonstrations of these process conﬁg-
urations separate cyclosporine via cooling crystallization,
without the need for any antisolvent or source of counterions
for salt formation, from a crude sample in acetone containing
up to 19 diﬀerent impurities.53,54 For this reason, the authors
explicitly consider purity as an additional measure of
crystallization performance. Due to the variation of sample
compositions that will be present in real processes, we do not
consider the eﬀect of diﬀerent process conﬁgurations on
cyclosporine crystal purity in this work. It is assumed that the
feed stream of cyclosporine in acetone contains negligible
amounts of impurities that would aﬀect the crystal purity
attained in these processes. In real applications, consideration
of crystal purity is imperative for application to meet the strict
purity requirements of pharmaceutical processes.16
For both processes with and without solids recycle, we
consider implementing one, two or three crystallizers in series.
Total residence times of 1−15 h operation of the whole cascade
are considered. For multiple MSMPRs, the operating temper-
ature of the ﬁrst crystallizer (T1) is varied (10, 15, and 20 °C)
and a ﬁnal crystallizer temperature (TN) of 0 °C is chosen, with
linear temperature decrease from T1 to TN from the beginning
to the end of the cascade. These operating variables are similar
to those used in the experimental demonstrations.53,54
For the process without recycle, the eﬀect of the API feed
concentration is also considered to demonstrate the sensitivity
of designs to varying feed conditions; feasible feed concen-
trations of 20, 25 and 30% w/w are considered here. The eﬀect
of solute feed concentration on MSMPR crystallization
performance has not been previously considered for continuous
cyclosporine crystallization.
For the processes with solids recycle, experimental
demonstrations have considered a total solids recycle extent
of 90%, i.e. 90% of slurry exiting the bottom of the gravity-
driven separator is fed back to the crystallization process.54 In
this work, we compare total solids recycles of 50, 70 and 90%.
We also conduct a systematic comparison of varying the feed
point location of the solid recycle stream via four diﬀerent
scenarios: the entire recycle stream fed to the ﬁrst, second or
third crystallizers only or the recycle stream equally distributed
between all crystallizers in the cascade.
3. STEADY-STATE PROCESS MODEL AND
SIMULATION METHODS
The following assumptions are involved in the formulation of
the steady-state MSMPR model:64
1. The fresh feed stream to the process is a homogeneous
mother liquor containing no API crystals.
2. Crystallization birth occurs by nucleation, and crystal
growth is linear. Growth is size-independent (i.e.,
McCabe’s ΔL law applies), and there is no crystal
breakage or attrition.
3. Product magma discharges at equilibrium from all
crystallizers; i.e., the mother liquor exiting the crystallizer
is saturated.
4. The contents of the crystallizer are perfectly mixed; i.e.
the supersaturation ﬁeld in the crystallizer is uniform, and
the product magma has the same composition as the
crystallizer contents.
All ﬂowsheets and plant designs produce 100 kg of
cyclosporine per annum. The steady-state process models for
all ﬂowsheet conﬁgurations describe one-dimensional crystal-
lization kinetics, population balance equations and process mass
balances. Simultaneous solution of these equations describes
continuous crystallization in a series of MSMPR crystallizers.
The proposed framework models steady-state MSMPR
crystallization of cyclosporine; MSMPR crystallizers are
operated continuously, and thus steady-state is the dominant
mode of operation during API production. The consideration
of dynamic operation (e.g., for start-up procedures) requires
extended modeling and solution of PDEs, which is beyond the
scope of this work, but has been investigated in the
literature.49,65
3.1. Crystallization Kinetics. The crystallization kinetics
equations describe the linear growth and nucleation rates of
API crystals as a function of the supersaturation and operating
temperature of the MSMPR crystallizers. The linear crystal
growth rate in MSMPR i, Gi, is described by the following
power law expression18
= −
+
−
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kg0 is the pre-exponential growth factor, Eag is the growth
energy barrier, R is the universal gas constant, Ti is the
operating temperature of MSMPR i, Ci is the API concentration
in the mother liquor within and discharged from MSMPR i and
g is the crystal growth exponent. The API saturation
concentration, Ci
sat, is a function of Ti, calculated via a
surrogate polynomial regressed from published temperature-
dependent saturation data for cyclosporine.55
= · + · +− −C T T(1.165 10 ) (2.000 10 ) 0.047isat 4 i2 4 i (2)
The nucleation rate in MSMPR i, Bi, is described by the
power law expression18
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+
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kb0 is the pre-exponential factor for nucleation, Eab is the
nucleation energy barrier, b is the crystal nucleation exponent,
Mi is the slurry density in MSMPR i and m is the exponent of
the slurry density. All crystallization kinetic parameters taken
from previous work are listed in Table 1.54
MSMPR crystallizers are applicable for substances with slow
crystallization kinetics. The proposed framework can be
implemented for any API whose crystallization kinetics are
slow, for which physical properties and crystallization kinetic
parameters are available and whose solubility varies signiﬁcantly
with temperature (i.e., API separation is amenable to cooling
crystallization) can be estimated experimentally or modeled.
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3.2. Population Balance Equations. The general one-
dimensional population balance model is described by a system
of ordinary diﬀerential equations (ODEs).
= −+ +G V
n
L
F n Fn
d
d1 1
1
N 1 N 1 1 1 (4)
= + − =− − + +GV
n
L
F n F n Fn i N
d
d
2...i i
i
i 1 i 1 N i N i i i (5)
Fi−1 and Fi are the volumetric ﬂow rates of streams entering
and leaving MSMPR i, respectively, FN+i is the recycle
volumetric ﬂow rate entering MSMPR i, N is the total number
of crystallizers, ni is the crystal population density function in
MSMPR i and L is the characteristic length of the crystal. For
the process without recycle, FN+i terms are equal to zero. The
system of ODEs formed by the population balance equations
are satisﬁed by the boundary condition, ni
0 = ni(L = 0),
corresponding to the population density of nuclei.
=n B
Gi
0 i
i (6)
The slurry density in MSMPR i is calculated from the
population density function as follows:50
∫ρ=M k n L Ldi v API i 3 (7)
kv is the crystal volume shape factor (= π/6 for spherical
crystals, assumed constant for linear crystal growth) and ρAPI is
the API crystal density. A typical value of ρAPI = 1.3 g cm
−3 for
solid APIs66 is assumed here due to the lack of physical
property data for cyclosporine.
3.3. Process Mass Balances. The steady-state mass
balances for each process assume no material accumulation
and account for volumetric changes due to API crystallization.
The general mass balance equations for processes are54
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F0 and C0 are the volumetric ﬂow rate and mother liquor API
concentration of the fresh feed stream, respectively. For the
process without recycle, FN+i terms are equal to zero.
For the solids recycle case, an additional mass balance around
the gravity-driven separator is required:54
=
−+
M
M
x(1 )N 1
N
(10)
where x is the clear liquor removal ratio.
For all processes, an API balance across mother liquor and
crystallized solid phases also gives the following expression for
the slurry density from the process mass balances:
= −−M C Ci i 1 i (11)
3.4. Process Yields. The crystallization yield is calculated
from the mother liquor API concentration exiting the ﬁnal
crystallizer relative to the feed concentration.
= −
⎛
⎝⎜
⎞
⎠⎟Y
C
C
100 1crystallization,NR/SR
N
0 (12)
The plantwide yield is calculated from the amount of
crystallized API in the product magma stream relative to the
total mass of API in the fresh process mother liquor feed
stream. For the process without recycle the crystallization and
plantwide yields are equal; i.e., the product stream is that
leaving the ﬁnal crystallizer (FN in Figure 1) and the product
stream is the concentrated magma leaving the bottom of the
gravity-driven separator withdrawn as product (not recycled,
F2N+3 in Figure 2). For the process with solids recycle, the
plantwide yield is calculated from the mass of crystallized API
withdrawn from the bottom of the gravity-driven separator as
product (F2N+3 in Figure 2) relative to the amount in the feed
mother liquor to the process (F0).
=Y Yplantwide,NR crystallization,NR (13)
= + +
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3.5. Environmental Impact Assessment. A measure of
the environmental impact of diﬀerent processes is essential in
addition to the calculation of attainable crystallization and
plantwide yields. Measuring the material eﬃciency of a process
provides an indication of the amount of waste that will be
produced, which in turn is a measure of the environmental
impact of the process. Green chemistry metrics allow the
quantitative comparison of the material eﬃciencies of diﬀerent
processes.67 The choice of an appropriate green chemistry
metric depends upon the studied process.68 The environmental
(E)-factor is a commonly used, ﬂexible green chemistry metric
that quantiﬁes the mass of waste produced per unit mass of
desired product.
=E m
m
waste
API (15)
We quantify the material eﬃciencies of diﬀerent ﬂowsheet
conﬁgurations via the E-factor in this work. For all
conﬁgurations, waste components are considered as the
unrecovered mother liquor streams. The process without
recycle has unrecovered mother liquor leaving in the product
magma from the ﬁnal crystallizer (FN in Figure 1); the process
with solids recycle has mother liquor removed from the top and
Table 1. Crystallization Kinetic Parameters for the Cooling
Crystallization of Cyclosporine54
parameter value units
kg0 1.13 × 10
7 m min−1
Eag/R 9.06 × 10
3 K
kb0 4.80 × 10
20 # m−3 min−1
Eab/R 7.03 × 10
3 K
g 1.33 
b 1.50 
m 2/3 
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bottom of the column (F2N+2 and F2N+3 in Figure 2,
respectively).
3.6. Calculation of Crystallizer Volumes. The calculation
of required crystallizer volumes is required for solutions of the
population balance equations in the steady-state process model
and for cost calculations. Required crystallizer volumes are
calculated from the total residence time of the MSMPR cascade
and the process volumetric ﬂow rates of the process. For N
crystallizers in series, the residence time of each crystallizer is
the total cascade residence time divided by N; thus, the
required crystallizer volume is calculated as
τ τ= =V F F
NN i i
i total
(16)
The model considers the residence times of the main process
stream in the MSMPR crystallizers only. The residence times of
streams in the solids recycle loop are not considered here due
to the small API capacity and crystallizer volumes. The eﬀect of
recycle stream residence times will become more signiﬁcant for
increased plant capacities and should be considered in scale-up
studies. For subsequent economic analyses, volumetric ﬂow
rates and crystallizer volumes are scaled to account for
crystallization and plantwide ineﬃciencies.
3.7. Algorithm and Code Structure. Figure 3 shows the
algorithm ﬂowchart for the solution of diﬀerent process
conﬁgurations for continuous cyclosporine crystallization in
MSMPR crystallizers. An initial guess must be made for the
vector of outlet concentrations of each MSMPR crystallizer
(Ci), which must lie between the crystallizer inlet concentration
(Ci‑1) and the saturation concentration at Ti (Ci
sat); this guess is
close to the saturation concentration for each crystallizer, which
allowed convergence when validating the model versus
experimental results.53,54,69 The slurry densities in each
crystallizer (Mi) are computed, which are used to solve mass
balances for the process’ volumetric ﬂow rates. Required
crystallizer volumes are calculated from the total cascade
residence time and the calculated volumetric ﬂow rates.
Crystallization kinetics, stream ﬂow rates and crystallizer
volumes are then incorporated into the population balance
equations. The population balance equations are then solved,
and the slurry densities are calculated. The diﬀerence between
the slurry densities calculated from the mass balance equations
and the population balance solutions form a system of
nonlinear equations that is solved by iterating upon the vector
of Ci values.
The process model is implemented and solved in MATLAB.
The population balance equations form a system of stiﬀ ODEs
which are solved using the built-in solver ode15s. The system of
nonlinear equations formed by the diﬀerences between slurry
densities calculated from mass balances and population balance
Figure 3. Algorithm ﬂowchart for the solution of the steady-state process model for continuous cyclosporine crystallization in MSMPR crystallizers.
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equations is solved using the built-in solver fsolve (with
tolerances of 10−6). A variety of initial guesses for Ci gave the
same converged results for all values used. The process model
has been validated by replicating process yields for various
experimental studies.53,54,69
4. ECONOMIC ANALYSES
Systematic cost analyses are essential to inform the selection of
economically viable process options. Our recent work59−63 has
utilized an established methodology for costing batch and CPM
processes.58 The studied processes are assumed to be
implemented at an existing pharmaceutical manufacturing site
with essential auxiliary structures already in place. 8000 h of
operation per year is considered. Here, we describe the costing
methodology used in this work.
4.1. Capital Expenditure (CapEx). Prices for equipment
of similar capacities to those considered here have been sourced
where possible; when such data are unavailable, the following
cost−capacity correlation is used:70
=
⎛
⎝⎜
⎞
⎠⎟P fP
S
S
n
B A
B
A (17)
Pj is the equipment purchase cost at capacity Sj. The exponent n
depends on the equipment item. Varying design considerations
between diﬀerent equipment capacities are accounted for via
the factor f. Values of n and f are found in the literature.70
Where the reference purchase costs (PA) are taken from the
past, chemical engineering plant cost indices (CEPCIs) are
used to account for inﬂation. All equipment capacities are
scaled to account for plantwide ineﬃciencies to meet the
speciﬁed plant capacity. MSMPR crystallizers are modeled as
forced circulation crystallizers, peristaltic pumps are used for
feed transfer, recycle and product streams,53,54 and the gravity-
driven separator is modeled as a solid settler. Table 2 gives
details for the purchase costs and scaling parameters in eq 17
for each equipment item used in processes with and without
solids recycle.
The sum of all inﬂation-adjusted equipment purchase costs
gives the Free-on-Board (FOB) cost. The Chilton method is
used to calculate the Battery Limits Installed Cost (BLIC).72
The installed equipment cost (IEC) is calculated as 1.43 times
the FOB. Process piping and instrumentation (PPI) costs are
calculated as 42% of IEC, respectively. The sum of IEC and PPI
gives the total physical plant cost (TPPC). A construction
factor of 0.3 is added to TPPC to calculate the BLIC.58
=IEC 1.43FOB (18)
=PPI 0.42IEC (19)
= +TPPC IEC PPI (20)
=BLIC 1.3TPPC (21)
Working capital costs are taken as 3.5% of annual material
costs (MATannual).
58 Contingency costs (CC) are calculated as
20% of the BLIC. The sum of working capital and contingency
costs (WCC) and BLIC gives the total capital expenditure
(CapEx) of the process.58
=WC 0.035MATannual (22)
=CC 0.2BLIC (23)
= +WCC WC CC (24)
= +CapEx BLIC WCC (25)
4.2. Operating Expenditure (OpEx). Annual operating
expenditure (OpExannual) is calculated as the sum of annual
material (MATannual), utilities and waste disposal (UWannual)
costs. Material purchase prices are sourced from various
vendors. All material requirements are scaled to account for
plantwide ineﬃciencies to meet the speciﬁed plant capacity
(100 kg per annum). Annual utilities costs (UTILannual) are
calculated as 0.96 GBP per kg of material input (total feed
mother liquor);58 a coeﬃcient of 460.8 is used to convert the
mass ﬂow rate to kg y−1 for economic analysis calculations.
Annual waste costs (Wasteannual) are 0.35 GBP per L of waste
produced;58 a coeﬃcient of 168 is used to convert the
volumetric ﬂow rate to L y−1.
ρ= +F CUTIL 460.8 ( )annual 0 acetone 0 (26)
ρ ρ
ρ= − +
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N
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= +UW UTIL Wasteannual annual annual (28)
= +OpEx MAT UWannual annual annual (29)
We consider all mother liquor unrecovered for all process
conﬁgurations. Labour costs are not considered here due to the
small scale of production and automated nature of CPM.
4.3. Total Costs. The total cost of the plant designs is
calculated as the sum of CapEx and inﬂation-adjusted OpEx
over the plant lifetime.
∑= +
+
τ
= r
Total Costs CapEx
OpEx
(1 )k
k
1
annual
(30)
where CapEx is the sum of BLIC and WCC (eq 25) and
OpExannual is the sum of MATannual and UWannual adjusted for
inﬂation over the total plant lifetime. Total material and utilities
and waste disposal costs (the sum of which give the total OpEx,
OpExtotal) are calculated and adjusted for inﬂation over the total
plant lifetime.
∑=
+
τ
= r
MAT
MAT
(1 )k
ktotal
1
annual
(31)
∑=
+
τ
= r
UW
UW
(1 )k
ktotal
1
annual
(32)
= +OpEx MAT UWtotal total total (33)
Table 2. Equipment Parameters for Calculating Scaled Equipment Purchase Costs in the Present Day
item ref. year ref. cost, PA (GBP) capacity basis ref. capacity, SA n f (%) ref.
crystallizer 2007 328 875 m3 3.00 0.53 10.33 70
pump 2015 958   1.00  71
gravity-driven separator 2007 207 900 L s−1 58 0.64 10.33 70
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A plant-operating lifetime (τ) of 20 years and an interest rate (r,
accounting for inﬂation) of 5% are considered. All CapEx is
assumed to occur in year 0, and operation is assumed to begin
in year 1.
The most economically viable process is that which
ultimately achieves the lowest total costs and environmental
impact (i.e., E-factors) over the speciﬁed plant lifetime. Total
costs (CapEx and OpEx components) are systematically
compared for each entire process conﬁguration.
5. RESULTS AND DISCUSSION
5.1. Attainable Yields and Material Eﬃciencies.
5.1.1. No Recycle. The eﬀect of API feed concentration was
considered for the continuous cyclosporine crystallization
without recycle. Figure 4 shows the attainable yields for a
varying number of crystallizers and total MSMPR cascade
residence time of 12 h. The results show that the considered
API feed concentration has a signiﬁcant impact on the attained
yield; this is an important variable due to potential ﬂuctuations
in feed composition to a continuous crystallization process.
Consideration of unit operations required to meet the speciﬁed
feed concentration for a designed crystallization process is
paramount to successful operation, and should be considered
for further investigations encompassing upstream unit oper-
ations prior to crystallization.
The results also show that increasing the number of
crystallizers and decreasing the operating temperature leads
to an increase in crystallization yield. Reducing the operating
temperature increases the supersaturation, which enhances the
yield. Increasing the number of crystallizers over which cooling
to the target temperature is attained also enhances the yield as
well as reducing the speciﬁc cooling duty per crystallizer.64
The eﬀect of varying the total cascade residence time for the
process without recycle was then investigated. Figure 5 shows
the attainable yields as a function of the number of crystallizers,
the operating temperature and the total cascade residence time
for a feasible API feed concentration of 25% w/w. The results
show ﬂattening proﬁles for all process conﬁgurations beyond a
total cascade residence time of 9 h, from which there are only
incremental increases in attainable yield. It is also observed that
using three crystallizers and operating the ﬁrst crystallizer at 10
°C gives the highest attainable yields for any total residence
time considered. These results show that using multiple
crystallizers allows higher attainable yields than a single
crystallizer for the same total residence time for certain
operating temperatures.
Figure 4. Attainable crystallization (plantwide) yields, Ycrystallization,SR = − ·( )1 100%CCN0 , for continuous cyclosporine crystallization without recycle
(total cascade residence time = 12 h).
Figure 5. Attainable crystallization (plantwide) yields, Ycrystallization,NR = − ·( )1 100%CCN0 , for continuous cyclosporine crystallization without recycle
as a function of total residence time (C0 = 25% w/w).
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Figure 6 shows the E-factors for the process without recycle
corresponding to the attainable yields presented in Figure 5.
The process conﬁguration with no recycle achieves very low E-
factors due to the high yields and simplicity of the process in
comparison with other puriﬁcation and separation technologies,
e.g. liquid−liquid extraction or antisolvent crystallization that
require an additional solvent to induce phase separation. The E-
factor can be as high as 200 for batch-dominated processes such
as those implemented in the pharmaceutical industry, whereas
continuously operated manufacturing methods such as
petroleum-based processes can have E-factors as low as 0.1.73
Pharmaceutical processes also have typically high E-factors due
to the inherent complexity of their processes involving
multistep syntheses, intermediate workups and puriﬁcations
and downstream operations required to meet the strict product
standards for pharmaceutical products.
5.1.2. Solids Recycle. Figure 7 shows the calculated
attainable crystallization yields for the process with solids
recycle (i.e., the amount of API crystallized from mother liquor
in the stream exiting the ﬁnal crystallizer, FN) for an API feed
concentration of 25% w/w. Crystallization yields improve with
increasing recycle ratio due to the enhanced crystal surface area
in the crystallizer.54 The eﬀect of the recycle feed point location
has also been investigated. It is shown that feeding the solids
recycle stream to the ﬁnal crystallizer provides the greatest
yields for all operating temperatures and residence times
considered. The eﬀect of these diﬀerent extents of recycle and
feed point location directly aﬀects the required crystallizer
volumes, which will impact the CapEx of the process; economic
analyses can further elucidate the most viable process
conﬁguration. It is also shown in Figure 7 that certain recycle
ratios (e.g., 90%) attain higher crystallization yields when using
a single crystallizer instead of multiple units. This result
highlights the need for systematic screening of diﬀerent process
options to establish viable conﬁgurations.
Figure 8 shows the plantwide yields (i.e., the amount of solid
API removed as product from the bottom of the gravity-driven
separator in stream F2N+3) following gravity-driven separation
for the process with solids recycle. In contrast to the results for
crystallization yields (Figure 7), increasing the recycle ratio
Figure 6. E-factors for continuous cyclosporine crystallization without recycle.
Figure 7. Attainable crystallization yields, Ycrystallization,SR = − ·( )1 100%CCN0 , for continuous cyclosporine crystallization with solids recycle as a
function of total residence time (C0 = 25 w/w %).
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leads to a decrease in plantwide yield. This is due the increased
amount of mother liquor containing uncrystallized API which is
discharged from the top and bottom of the gravity-driven
separator with increasing recycle ratios. This also incurs a
decreased plant productivity due to the increasing amount of
solids fed back to the crystallizer cascade as opposed to being
withdrawn as product. This eﬀect is a result of the ﬂowsheet
conﬁguration we have modeled here, based upon the
demonstrated experimental setup.45 This is an important
implication when considering the design and implementation
of continuous crystallization processes. The loss of API in
mother liquor streams can be controlled by altering the clear
mother liquor removal ratio (x), but this will also aﬀect the
attainable crystallization yield. Further investigation via a wider
multivariate analysis of the process with solids recycle is
required to identify the best conﬁguration for this process.
Figure 9 shows the E-factors corresponding to the plantwide
yields for the process with solids recycle. The waste streams of
the process with solids recycle are the mother liquor streams
removed from the top and bottom of the gravity-driven
Figure 8. Attainable plantwide yields, Yplantwide,SR = ·+ +( ) 100%F MF C2N 3 N 10 0 , for the continuous crystallization of cyclosporine with solids recycle as a
function of total cascade residence time (C0 = 25 w/w %).
Figure 9. Plantwide E-factors for the continuous cyclosporine crystallization with solids recycle as a function of total cascade residence time (C0 = 25
w/w %).
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separator. For increased recycle ratios, the E-factors of diﬀerent
process options increase due to the decreasing plantwide yields
with increasing recycle ratio. This is due to the increased
amount of mother liquor which is discharged from the process
as waste with increasing recycle ratio, as well as the increased
material requirements needed to account for plantwide
ineﬃciencies to meet the speciﬁed plant capacity. Despite the
elevated E-factors for higher recycle ratios, the values for all
processes considered are acceptable for pharmaceutical
processes.73
5.2. Crystallizer Volume Design. From the calculated
attainable crystallization and plantwide yields presented, it is
shown that beyond certain residence times, there is no
appreciable increase in yield. Designing cascades with longer
residence times (i.e., crystallizers with working volumes
signiﬁcantly larger than necessary) will result in economically
unviable process designs. The eﬀect of diﬀerent process
conﬁgurations impacts the total crystallizer volumes required
which directly aﬀects the capital costs of the design. We
calculate crystallizer volumes as a function of operating
temperature, the number of crystallizers and the extent and
feed point location of solids recycle. Maximum residence times
beyond which there is no appreciable increase in yield
(considered to be <1% relative increase in yield) were selected
for economic analyses of diﬀerent process options, which are
shown in Table 3.
5.2.1. No Recycle. Required crystallizer volumes for the
process without recycle are shown in Figure 10. Increasing the
number of crystallizers allows signiﬁcantly lower total
crystallizer volumes due to the higher yields attainable at
shorter residence times. When multiple crystallizers are used,
the operating temperature has only a small eﬀect on the total
crystallizer volume due to its small eﬀect on the process yields.
When three crystallizers are used, operating the ﬁrst crystallizer
at 20 °C leads to a signiﬁcant increase in total crystallizer
volume (compared to operating at 10 and 15 °C) due to the
longer residence time, and thus total crystallizer volume,
required to reach the maximum attainable yield.
5.2.2. Solids Recycle. Required crystallizer volumes for the
process with solids recycle are shown in Figure 11,
corresponding to the maximum residence times listed in
Table 3. Similar eﬀects of increasing the number of crystallizers
and varying operating temperatures are observed as for the
process without recycle.
Increasing the extent of recycle leads to larger crystallizer
volumes as the internal ﬂow rates of the system become larger.
The eﬀect of feed point location on crystallizer volumes is also
important; when the recycle stream is fed to the ﬁrst
crystallizer, all crystallizers have similar volumes as a large
volumetric ﬂow rate passes through all. A similar eﬀect is
observed when the recycle stream is equally distributed
between all crystallizers. However, when the recycle stream is
fed to the second or third crystallizers, only these crystallizers
must be larger to accommodate the higher throughput.
5.3. Economic Analyses. In this section, we present the
results of the economic analyses of diﬀerent process options for
the established maximum residence times listed in Table 3.
Crystallizer purchase costs are a signiﬁcant portion of BLIC,
and thus the CapEx, so correlating crystallizer volumes with
process costs provide insight into diﬀerences in total costs
between diﬀerent process conﬁgurations. We then present total
cost components for all conﬁgurations computed using the
established costing methodology described previously.58
5.3.1. No Recycle. Figure 12 shows the total costs and the
contributing components of diﬀerent conﬁgurations for the
process without recycle. In all scenarios, the BLIC contributes
the most signiﬁcant portion of CapEx; WCC provides a lesser
contribution to CapEx due the automated nature of continuous
manufacturing processes. The process using a single crystallizer
operating at 0 °C has the lowest total costs due to the
signiﬁcantly reduced CapEx (BLIC and WCC) costs. This
result shows that increasing the number of crystallizers, and
thus the number of associated pumps, has a signiﬁcant impact
on the total costs of the plant at this operating scale.
The most signiﬁcant contribution toward OpEx is utilities
and waste handling (UW). Material costs for this process are
relatively small due to the nature of the crystallization process;
i.e., we only consider cooling crystallization of an API from
mother liquor. Material costs for more elaborate processes (e.g.,
encompassing syntheses, workups and puriﬁcations prior to
crystallization) are much more signiﬁcant in comparison to the
Table 3. Total Cascade Residence Times (h) Used for
Economic Analyses, Corresponding to Maximum Yields
no recycle
T1 (°C)
no. MSMPRs recycle feed point 0 10 15 20
1 n/a 9 − − −
2 n/a − 6 6 6
3 n/a − 3 3 6
solids recycle = 50%
T1 (°C)
no. MSMPRs recycle feed point 0 10 15 20
1 MSMPR 1 6 − − −
MSMPR 1 − 6 6 6
2 MSMPR 2 − 3 3 6
equal distribution − 3 6 6
3 MSMPR 1 − 3 3 6
MSMPR 2 − 3 3 6
MSMPR 3 − 3 3 3
equal distribution − 3 3 6
solids recycle = 70%
T1 (°C)
no. MSMPRs recycle feed point 0 10 15 20
1 MSMPR 1 6 − − −
MSMPR 1 − 3 6 6
2 MSMPR 2 − 3 3 3
equal distribution − 3 6 6
3 MSMPR 1 − 3 3 6
MSMPR 2 − 3 3 3
MSMPR 3 − 1 1 3
equal distribution − 3 6 3
solids recycle = 90%
T1 (°C)
no. MSMPRs recycle feed point 0 10 15 20
1 MSMPR 1 3 − − −
MSMPR 1 − 3 3 3
2 MSMPR 2 − 1 1 1
equal distribution − 3 3 3
3 MSMPR 1 − 3 3 3
MSMPR 2 − 1 1 3
MSMPR 3 − 1 1 1
equal distribution − 1 3 3
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continuous cooling crystallization process considered here. It is
also observed that OpEx components (materials, utilities and
waste) are relatively consistent across all scenarios for the
process with no recycle; this is due to the material requirements
and waste quantities being relatively similar across all processes,
despite the varying number of crystallizers and operating
temperatures. Explicit consideration of the eﬀect of varying
operating temperatures and pumping duties on the utilities
costs is not considered in the methodology used here. This will
likely lead to greater OpEx costs when operating a single
crystallizer at 0 °C as the cooling duty is burdened on one
vessel only. Methodologies which explicitly calculate varying
costs of utilities with diﬀering pumping requirements and
cooling duties should be implemented where possible.
5.3.2. Solids Recycle. Figure 13 shows the cost components
of diﬀerent conﬁgurations for the process with solids recycle.
The most cost optimal conﬁguration is using two crystallizers
with all recycle fed to the ﬁrst crystallizer, operating at 10 °C.
As before, increasing the number of crystallizers signiﬁcantly
increases the CapEx of the process.
Figure 10. Calculated crystallizer volumes for residence times provided in Table 3 for the process without recycle (C0 = 25% w/w).
Figure 11. Calculated crystallizer volumes for residence times provided in Table 3 for the process with solids recycle (C0 = 25% w/w).
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Increasing the extent of solids recycle and feeding the recycle
to the ﬁrst crystallizer leads to increased total costs due to the
increased crystallizer volumes required to handle higher
material throughputs. The greatest costs incurred are when
the recycle stream is evenly split between all crystallizers due to
the large vessel volumes required to accommodate the
increased internal ﬂow rates and the lower yields attained in
comparison to when the recycle stream is fed to the ﬁnal
crystallizer. As before, BLIC contributes a signiﬁcant portion to
CapEx and UW contributes a signiﬁcant portion to OpEx. The
increased utilities costs with increasing recycle ratios, i.e.
additional pumping requirements, are not explicitly considered
here, but will lead to increased OpEx for scenarios with higher
recycle ratios. Consideration of these factors is essential for
accurate cost comparisons.
5.3.3. Cost Components per Total Crystallizer Unit
Volume. In the previous subsection, Figures 12 and 13
compare absolute total cost components for all process
conﬁgurations considered for the total cascade residence
times listed in Table 3. As explained previously, the selection
of these total cascade residence times is such that the designed
crystallizers are not oversized; i.e., no unnecessary additional
capital costs for crystallizers are incurred for only incremental
increases in yield. However, this can lead to unfair cost
comparisons due to the diﬀerences in total cascade residence
times, and thus diﬀerent crystallizer volumes, which signiﬁ-
cantly aﬀects CapEx. We have calculated the total cost
components normalized with respect to the total crystallizer
volume in MSMPR cascades for both processes with and
without solids recycle to allow an alternative economic
comparison of diﬀerent conﬁgurations.
Figure 12. Cost components for the continuous cyclosporine
crystallization without recycle (C0 = 25% w/w).
Figure 13. Cost components for the continuous cyclosporine crystallization with solids recycle (C0 = 25% w/w).
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Figure 14 shows normalized cost components for the process
with no recycle, and the process with 50% solids recycle fed to
the ﬁrst crystallizer only. When one crystallizer is implemented,
the normalized total costs are greater when solids recycle is
implemented, due to the increased crystallizer volume required
to handle recycle ﬂow rates, which incurs greater CapEx.
However, when two or three crystallizers are implemented, the
process with solids recycle has lower normalized cost
components. It is also shown that for both processes with
and without recycle, there is a large diﬀerence between
operating the ﬁrst crystallizer at 15 and 20 °C when three
crystallizers are implemented; this is due to the sharp increase
in total crystallizer volumes for both cases.
These results indicate that the cost components of the
process are sensitive to the selection of total cascade residence
time for crystallization process design; i.e., if diﬀerent residence
times were selected for the process with solids recycle, then it
should be more economically viable than the process with no
recycle. This demonstrates the importance of rigorous process
analysis and fair comparisons of design and operating variables
for economic analyses of candidate conﬁgurations.
6. DISCUSSION
Continuous crystallization using a cascade of MSMPR
crystallizers has been systematically compared via steady-state
process modeling, comparing computed attainable yields,
material eﬃciencies and total cost components. The aim of
this work was to allow rigorous evaluation of economically
viable options for continuous cyclosporine crystallization.
Continuous cyclosporine crystallizations for diﬀerent process
conﬁgurations (with and without solids recycle) have been
compared as a function of the number of implemented
crystallizers, total cascade residence times, operating temper-
atures, varying extents of solid recycle and diﬀerent recycle feed
point locations. Crystallization and plantwide yields, E-factors,
required crystallizer volumes and total cost components are
compared for diﬀerent process conﬁgurations to evaluate the
most economically viable process option. We have also
calculated total cost components normalized with respect to
the total crystallizer volume to highlight the sensitivity of the
designs to the total cascade residence time for economic
analyses.
Crystallization yields are shown to increase for greater total
residence time and number of crystallizers, lower operating
temperatures and higher recycle ratios. However, increased
recycle ratios incur lower plantwide yields and higher E-factors
due to greater losses of API and solvent in discharged mother
liquor streams. This eﬀect is a consequence of the equipment
arrangement in the ﬂowsheet based upon an experimental
demonstration.45 Future work should compare alternative
arrangements for solids recycle to mitigate losses with increased
solids recycle.
The most economically viable conﬁguration for the process
without recycle implements a single crystallizer operating at 0
°C, incurring total costs of 25 488 GBP. For the process with
solids recycle, the most economically viable process option
implements two crystallizers with 50% solids recycle fed to the
second crystallizer only, operating the ﬁrst crystallizer at 10 °C,
incurring total costs of 45 660 GBP. However, as shown from
the normalized cost components with respect to total
crystallizer volume, these cost estimates are very sensitive to
the total cascade residence time of diﬀerent conﬁgurations.
Future work should consider a more systematic methodology
for economic analyses. The CapEx incurred when implement-
ing multiple crystallizers and the gravity-driven separation
column, for the process with solids recycle, leads to high total
costs. Utilities and waste handling costs contributing to OpEx
for other conﬁgurations lead to economically inferior processes
compared to the process without recycle. However, the
economic analysis methodology implemented here does not
explicitly consider the eﬀect of diﬀerent operating temperatures
and extents of recycle (which directly impact cooling and
pumping duties of crystallizers and peristaltic pumps,
respectively) on OpEx contributions to total costs. This may
lead to reduced cost beneﬁts when implementing a single
crystallizer with a high cooling duty in comparison to other
conﬁgurations which distribute the total cooling duty among
multiple vessels. Future work should consider these factors for a
more accurate evaluation of economically viable processes.
The steady-state process modeling results presented here are
based upon several key assumptions of the MSMPR model.
Neglecting the presence of impurities in the process feed
stream is an important assumption; crystal purity is an essential
parameter due to the strict regulations imposed on
Figure 14. Cost components per total crystallizer unit volume for continuous cyclosporine crystallization without recycle (left) and with 50% solids
recycle fed to the ﬁrst crystallizer only (right).
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pharmaceutical products. Moreover, the results are also strongly
dependent on the limited set of operating variables (i.e., the
number of crystallizers in series, total cascade residence time,
operating temperature, extent and location of solids recycle).
While the set and range of operating variables considered here
are limited, we have chosen these ranges in accordance with
those investigated in the experimental demonstrations of
continuous cyclosporine crystallization.52−54 The process
model has been described in enough detail such that the eﬀect
of operating variables beyond the sets considered here can be
considered by an expert reader.
This work considers the steady-state process modeling and
simulation for continuous cyclosporine crystallization and does
not consider upstream synthetic steps. The continuous ﬂow
synthesis or cyclosporine is not modeled in this work due to the
lack of experimental demonstrations and kinetic data required
for accurate reactor design. However, the results presented here
provide a direct indication of which crystallization processes
will lead to the best-performing process conﬁgurations.
Operating MSMPR crystallizers in a closed-loop can allow
smaller crystallizer volumes and reduced material requirements
for continuous crystallization conﬁgurations, but issues with
fouling and encrustation can make such setups unfavorable.74 A
systematic comparison of diﬀerent processes with and without
closed-loop arrangements is required to establish the best
process conﬁguration. While the current work does not
consider downtime for dealing with fouling issues, operating
a closed-loop process will make fouling eﬀects more signiﬁcant;
economic analyses would thus need to consider equipment
downtime and additional standby equipment to ensure fully
continuous operation of the process. The current work
considers processes without closed-loop operation only, in
accordance with the experimental demonstrations of the
processes with and without solids recycle.53,54
The modeling of continuous crystallization processes using
MSMPR crystallizers is a multivariate problem, which requires
rigorous mathematical methods to establish the best process
conﬁguration. Despite the systematic methods we have used
here to investigate the design space for diﬀerent ﬂowsheet
conﬁgurations for continuous cyclosporine crystallization, it is
imperative to perform mathematical optimizations of such
processes to minimize the total costs. Previous work has
performed optimization of yield and purity of cyclosporine in a
series of MSMPR crystallizers without recycle by varying the
temperature and residence time of each crystallizer;53 however,
no such optimization study has been performed for the process
implementing solids recycle, and no study has yet optimized
MSMPR crystallization processes with total costs as the
objective function. Such work is imperative to establish
economically viable options for continuous crystallization
prior to further development.
7. CONCLUSIONS
The present study implements a technoeconomic analysis of
two diﬀerent conﬁgurations for the continuous crystallization of
cyclosporine: with and without solids recycle, based on
experimental demonstrations.53,54 A steady-state process
model for a cascade of continuous MSMPR crystallizers
incorporating population balance equations, crystallization
kinetics and process mass balances for diﬀerent ﬂowsheet
permutations allows calculation of yields for diﬀerent process
conﬁgurations and operating variables, including varying the
number of crystallizers, operating temperatures, total cascade
residence times, API feed concentration and extent and feed
point location of recycle streams. The environmental impacts/
material eﬃciencies of diﬀerent process conﬁgurations are
evaluated using the widely implemented E-factor. Cost analyses
using an established methodology for CPM processes allow
comparison of the economic viability of the process
conﬁgurations considered.
The capital expenditures incurred using multiple crystallizers
and a gravity-driven separation column as well as high waste
handling costs make processes with solids recycle economically
inferior to those without recycle. In addition to achieving the
lowest total costs, the process using a single crystallizer with no
recycle also achieves very low E-factors (<10) in comparison to
typical pharmaceutical manufacturing processes and other
process conﬁgurations considered here. Total cost components
normalized with respect to total crystallizer volume imple-
mented show the sensitivity of selected residence times on
economic analyses and cost comparisons of diﬀerent process
conﬁgurations. Due to the complex interplay of operating
variables considered here, technoeconomic optimization with
respect to total costs is required to establish the optimal process
conﬁguration and operating variables for development of the
continuous crystallization of cyclosporine. This work demon-
strates the value of conducting process modeling studies prior
to costly development and scale-up of CPM processes.
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■ NOMENCLATURE AND ACRONYMS
Latin Letters and Acronyms
API Active pharmaceutical ingredient
Bi Crystal nucleation rate (# m
−3 min−1)
b Crystal nucleation exponent ()
BLIC Battery limits installed costs (GBP)
C0 Mother liquor API concentration of the fresh
feed stream (g mL−1)
Ci API concentration in product magma of
MSMPR i (g mL−1)
Ci
sat API saturation concentration at Ti (g mL
−1)
CapEx Capital expenditure (GBP)
CC Contingency costs (GBP)
CEPCI Chemical engineering plant cost index
CPM Continuous pharmaceutical manufacturing
E Environmental factor ()
Eag Crystal growth activation energy (J mol
−1)
F0 Volumetric ﬂow rate of the fresh feed stream
(mL min−1)
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Fi Volumetric ﬂow rate of stream i (mL min
−1)
f Correction factor in eq 17
FOB Free-on-Board Costs (GBP)
Gi Crystal linear growth rate (m min
−1)
g Crystal growth exponent ()
IEC Installed equipment costs (GBP)
kb0 Pre-exponential factor for crystal nucleation (#
m−3 min−1)
kg0 Pre-exponential factor for crystal growth (m
min−1)
kv Crystal volume shape factor (= π/6 for spherical
crystals)
L Crystal characteristic length (m)
Mi MSMPR slurry density (g mL
−1)
MATannual Annual material costs (GBP y
−1)
MATtotal Total material costs over the plant lifetime
(GBP)
MSMPR Mixed Suspension-Mixed Product Removal
mAPI Mass of recovered crystallized API (g min
−1)
mwaste Mass of waste API (g min
−1)
N Number of MSMPRs in series ()
n Exponent in eq 17
ni Crystal population density (# m
−3 m−1)
ni
0 Nuclei population density (# m−3 m−1)
OBC Oscillatory Baﬄed Crystallizer
ODE Ordinary diﬀerential equation
OpExannual Annual operating expenditure (GBP y
−1)
OpExtotal Total operating expenditure over the plant
lifetime (GBP)
Pj Equipment purchase cost at capacity j (GBP)
PF Plug ﬂow
PPI Process piping and instrumentation costs (GBP)
R Universal gas constant (= 8.314 J mol−1 K−1)
r Interest rate (%)
Sj Capacity of equipment (varying units)
Ti Operating temperature of MSMPR i (°C)
TPPC Total physical plant cost (GBP)
UWannual Sum of annual utilities and waste disposal costs
(GBP y−1)
UWtotal Total utilities and waste disposal costs over the
plant lifetime (GBP)
UTILannual Annual utilities costs (GBP y
−1)
Vi Volume of MSMPR i (mL)
WC Working capital costs (GBP)
WCC Working capital and contingency costs (GBP)
x Clear liquor removal ratio in gravity-driven
separation column for continuous crystallization
process with solids recycle ()
Ycrystallization Crystallization yield (%)
Yplantwide,NR/SR Plantwide API yield for process without/with
solids recycle (%)
Greek Letters
ρAPI API solid crystal density (g cm
−3)
ρacetone Acetone density at Ti (g mL
−1)
τ Plant operation lifetime (y)
τi Residence time in MSMPR i (h or min)
τtotal Residence time of total crystallizer cascade (h or min)
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